Navigation Links
Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
Date:1/27/2009

CALGARY, Jan. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today that patient enrolment has begun in a U.K. translational clinical trial investigating intravenous administration of REOLYSIN(R) in patients with metastatic colorectal cancer prior to surgical resection of liver metastases. The principal investigator is Professor Alan Melcher of St. James's University Hospital.

"This study allows us to assess a resected tumour after REOLYSIN(R) treatment has been administered, giving us vital information about how effective REOLYSIN(R) delivery really is in patients," said Prof. Melcher. "REOLYSIN(R) will be given to patients before their planned operation, which is part of the patient's standard clinical care. In addition to possible benefit to patients, this data will tell us more about how REOLYSIN(R) kills cancer cells; helping to guide future research and development of the agent."

The trial (REO 013) is an open-label, non-randomized, single centre study of REOLYSIN(R) given intravenously to patients for five consecutive days in advance of their scheduled operations to remove colorectal cancer deposits metastatic to the liver. Patients will comprise two groups receiving REOLYSIN(R), either at an early (21 to 10 days) or late time point (less than 10 days) before surgical resection. After surgery, the tumour and surrounding liver tissue will be assessed for viral status and anti-tumour effects.

"We are pleased that our U.K. colleagues are sponsoring additional clinical research using REOLYSIN(R)," said Dr. Brad Thompson, President and CEO of Oncolytics. "With the U.S. National Cancer Institute trials underway, three REOLYSIN(R) trials are now being sponsored by our collaborators."

The primary objectives of the trial are to assess the presence, replication and anti-cancer effects
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
2. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
3. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
4. Researchers at Axial Biotech Develop a DNA Test for Scoliosis
5. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
6. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
7. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
8. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
9. Pulmo BioTech Inc. Completes Bio-Distribution Studies
10. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
11. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 More than a third of ... of those with private insurance, filled a prescription for an ... report in this week,s Morbidity and Mortality Weekly Report (MMWR). ... providers to treat moderate to severe pain.  They are also ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... Cord Blood America, Inc. ( www.cordblood-america.com ) (OTC Bulletin Board: ... Preliminary Proxy Statement, Schedule 14A, with the U.S. Securities & ... for shareholders detailing why a "YES" vote to increase the ... As we reflect upon the 2014 fiscal year ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... Reportlinker.com announces that a new market research ... Innovations in Wound Care Devices and ... Introduction Wound ... range of sizes, shapes, stages, and types ...
... 2012 /PRNewswire-iReach/ -- Global Information, Inc. (GII) is ... Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts ... The Insulin Delivery Devices Market is ... $11 Billion by 2017 GlobalData estimated ...
Cached Medicine Technology:Innovations in Wound Care Devices and Dressings 2Innovations in Wound Care Devices and Dressings 3Innovations in Wound Care Devices and Dressings 4Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 2Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 3Insulin Delivery Devices - Increasing Prevalence of Diabetes to Drive the Market 4
(Date:1/23/2015)... Phoenix, AZ (PRWEB) January 23, 2015 Hastings ... personal injury matters, reports a record number of legal representation ... Statistically speaking, there has been a steady rise in the ... at work and at home throughout the Valley. With that ... their accident be reviewed by an experienced law firm. Hastings ...
(Date:1/22/2015)... January 22, 2015 Liberty University has received ... program from the Council for Accreditation of Counseling ... of Liberty’s Center for Counseling & Family Studies , ... of the university’s new School of Behavioral Sciences. Prior to ...
(Date:1/22/2015)... Woodloch Pines, an all-inclusive family resort ... as the number one best large hotel for families in ... for their annual Travelers’ Choice Awards. , TripAdvisor represents ... is home to millions of unbiased and honest traveler reviews. ...
(Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
(Date:1/22/2015)... 2015 Blue Cross and Blue Shield of ... what it means to “Live Fearless.” , The ... share their stories about how they or someone they know ... by living in the moment. By telling these types of ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2
... 26 (HealthDay News) -- If you,re told that your child ... carefully consider the situation, advises an expert. "Take ... respond defensively with ,not my child., Understand that your child ... health services at Saint Joseph,s University in Philadelphia, said in ...
... high body mass index (BMI) between 9 and 12 years of ... blood insulin levels (all risk factors for developing heart disease) by ... bmj.com today. Reassuringly, say the authors, children with ... reach adolescence have better heart disease risk profiles than those who ...
... Mammals began to grow much larger after dinosaurs became extinct ... international team of researchers analyzed the fossils of major groups ... size increased from a maximum of about 10 kilograms (22 ... maximum of 17 tonnes (18.7 U.S. tons) after dinosaurs became ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... who took a popular class of heartburn drugs while ... heightened risk of birth defects, a large Danish study ... inhibitors (PPIs), include blockbusters such as Prilosec (omeprazole), Prevacid ...
... outbreaks in refugee camps in earthquake-wracked Haiti, a group ... University, and the International Vaccine Institute (IVI) have urged ... cholera vaccines for future humanitarian use. "The ... stockpile of several million doses of cholera vaccine would ...
... Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- There,s encouraging ... babies. Children whose mothers took certain anti-seizure medications while breast-feeding ... 3, a new study finds. The multi-center study looked ... common antiepileptic drugs, and found no difference in IQ levels ...
Cached Medicine News:Health News:Parents of Bullies Urged to Open Lines of Communication 2Health News:A high BMI in childhood linked to greater heart disease risk in adolescence 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 2Health News:No Link Between Heartburn Drugs and Birth Defects: Study 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 2Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 3Health News:Experts urge US to create emergency cholera vaccine stockpile for humanitarian use 4Health News:Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests 2Health News:Women Taking Certain Epilepsy Drugs Can Safely Breast-Feed, Study Suggests 3
... Guidants 20-year history, the VOYAGER RX Dilatation ... treatment outcomes. It combines a new low ... profile shaft,more flexible markers, and short taper ... and tortuous anatomy with even greater confidence, ...
Test for AFP...
Enzyme Immunoassay for the Quantitative Measurement of Ovarian Cancer Antigen CA-125 in Human Serum...
For the quantitative measurement of human prostatic acid phosphatase (PAP) in human serum....
Medicine Products: